• Neena B. Schwartz Professor of Chemistry and Biomedical Engineering
• Professor of Biochemistry and Molecular Genetics

PhD (1999), California Institute of Technology

The Kelley research group uses a highly multidisciplinary approach at the intersection of chemistry, biology, and engineering to develop novel solutions for biomedicine and biological research. A variety of nanoscience-enabled projects are underway that focus on the discovery of new therapeutic targets and agents as well as new technologies for the molecular-level diagnosis of disease.

Using a new platform that relies on nanoparticle-based stratification of complex cell libraries, the Kelley group is discovering druggable targets relevant to the treatment of cancer, inflammatory disease, and other chronic conditions. This same technology is being utilized to develop next-generation cell therapies that can be precisely engineered to provide maximal benefit to patients.

The Kelley group also works extensively with nanostructured electrochemical sensing platforms that can be used to develop implantable sensors for a wide variety of molecular biomarkers. The ability to continuously monitor panels of biomarkers will inform our understanding of disease and transform our ability to treat and prevent it.